Natera Inc Stock Price, News & Analysis

Natera (NASDAQ: NTRA) was named to Fast Company’s 2025 Next Big Things in Tech list on October 16, 2025, recognized for its Signatera personalized molecular residual disease (MRD) test.

Signatera is a custom blood test that uses circulating tumor DNA to detect and quantify residual cancer, with clinical validation across multiple cancer types, >140 peer‑reviewed papers, and current ordering by more than 50% of U.S. oncologists. Fast Company selected Signatera as one of five honorees in the health and medicine category for its potential to impact cancer detection, monitoring, and treatment decisions.

Natera (NASDAQ: NTRA) will host an investor conference call and webcast on Oct 23, 2025 at 5:00 a.m. PT (8:00 a.m. ET) to discuss muscle-invasive bladder cancer data being presented at ESMO.

The discussion will cover results from the randomized phase 3 IMvigor011 trial and from Checkmate 274, with Professor Thomas Powles, lead PI of IMvigor011, joining the call. Live dial-in and webcast access are provided; a replay will be available at the company investor website.

Natera (NASDAQ: NTRA) announced that 14 studies featuring its Signatera ctDNA/MRD technology will be presented at the ESMO Congress, Oct 17–21, 2025 in Berlin, including six oral presentations. The IMvigor011 trial (Genentech/Roche) was selected for a Presidential Symposium on Oct 20; topline results were reported in August and the oral will include additional data on Signatera’s prediction of disease-free survival (DFS) and overall survival (OS) benefit from adjuvant atezolizumab in muscle-invasive bladder cancer (MIBC).

Key disclosed data: CheckMate 274 MRD analysis showed DFS for Signatera-positive patients treated with nivolumab of 7.4 months vs 2.8 months for placebo (HR: 0.35), while Signatera-negative patients showed no significant DFS improvement. Multiple other oral presentations cover colorectal, breast, renal, lung, and early cancer detection studies.

Natera (NASDAQ: NTRA) has reached a significant milestone in its EXPAND clinical trial, with enrollment exceeding 1,600 patients. The trial evaluates Fetal Focus™, a single gene noninvasive prenatal test (NIPT) for inherited conditions.

Initial results from EXPAND demonstrated 91% sensitivity, successfully identifying all 5 cases of homozygous variants. The trial, initiated in 2023, is distinguished by its comprehensive validation approach, confirming both positive and negative results through diagnostic testing.

Fetal Focus™ serves as an alternative testing option when biological fathers are unavailable for carrier testing, though testing both partners remains the gold standard. Natera expects to report comprehensive trial analysis in Q4 2025.

Natera (NASDAQ: NTRA) has published a groundbreaking study in the Journal of Clinical Oncology - Precision Oncology validating its Signatera™ test for testicular cancer. The multi-institutional study, analyzing 324 plasma samples from 74 patients, demonstrated that Signatera significantly outperformed standard serum tumor markers (STM) in predicting patient outcomes.

The study revealed impressive detection rates with Signatera showing 91.6% positivity for stage I and 100% for stages II and III. Notably, Signatera-positive patients showed significantly shorter event-free survival compared to Signatera-negative patients, with a hazard ratio of 12.45 (p<0.0001) during surveillance, while conventional STMs failed to show significant correlation with outcomes.

Natera (NASDAQ: NTRA) has published a new study in the Journal of Clinical Oncology Precision Oncology validating its Signatera™ test for monitoring uterine cancer recurrence. The multi-center study analyzed 233 plasma samples from 61 patients with stage I/II uterine cancer.

The study demonstrated that Signatera achieved 100% detection of cancer recurrences before clinical confirmation, with a median lead time of 3.1 months. The test proved highly prognostic in both postoperative (HR=7.6) and post-definitive therapy (HR=25.4) settings, outperforming traditional risk assessment methods. Notably, no patients who tested consistently negative with Signatera experienced recurrence.

Natera (NASDAQ: NTRA) provided an update on its patent litigation with NeoGenomics. The U.S. District Court for the Middle District of North Carolina invalidated certain claims in two patents related to NeoGenomics' v1.1 RaDaR test. However, this ruling does not affect U.S. Patent No. 11,519,035, which previously secured both preliminary and permanent injunctions against NeoGenomics' RaDaR v1.0 product.

The company is considering its options, including an appeal and enforcement of other patents. Natera emphasizes its strong intellectual property position with over 500 issued or pending patents worldwide and remains committed to protecting its innovation investments.

Natera (NASDAQ: NTRA) has announced the activation of the ARCHER (NRG-GU015) trial, a pivotal Phase III study in muscle-invasive bladder cancer (MIBC). The study will evaluate whether a shorter radiation course can match current standard-of-care outcomes, incorporating Natera's Signatera™ personalized molecular residual disease (MRD) test as a secondary endpoint.

The trial, sponsored by NRG Oncology through the National Cancer Institute, will involve over 100 sites across the U.S. and Canada. Signatera will monitor circulating tumor DNA (ctDNA) clearance patterns to predict treatment response and recurrence, with additional exploration of urine tumor DNA. The test has been clinically validated to detect MIBC recurrence earlier than standard imaging.

This initiative builds on Natera's existing MIBC clinical evidence, including positive results from the IMVigor011 trial, which demonstrated Signatera's effectiveness in predicting immunotherapy benefits post-cystectomy.

Natera (NASDAQ: NTRA) announced upcoming presentations at the 2025 International Association for the Study of Lung Cancer (IASLC) World Conference in Barcelona, Spain from September 6-9. The company will showcase new data demonstrating the clinical utility of its Signatera™ technology in lung cancer patients.

A key highlight includes an oral presentation featuring analysis of Signatera Genome in early-stage, resectable non-small cell lung cancer (NSCLC) patients, showing its prognostic value for recurrence-free and overall survival in post-surgical molecular residual disease assessment. Three presentations will cover various aspects of Signatera's application in lung cancer monitoring and treatment outcomes.